Skip to main
SLS
SLS logo

SLS Stock Forecast & Price Target

SLS Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

SELLAS Life Sciences Group Inc is well-positioned for future growth due to its advanced product candidates, particularly galinpepimut-S, which is currently in Phase 3 trials, and GFH009, a CDK9 inhibitor that complements its immunotherapy pipeline. The company's strategic focus on addressing significant unmet needs in cancer treatment enhances its market potential, particularly in light of the increasing prevalence of resistant relapsed patients. Furthermore, the positive advancements in clinical positioning and community relationships bolster SELLAS's operational capabilities and future commercial efficiencies, contributing to a favorable long-term outlook.

Bears say

SELLAS Life Sciences Group Inc is facing significant financial challenges that contribute to a negative outlook on its stock. The inability to secure additional resources and address high operational costs could hinder the company's progress in advancing its product candidates, particularly galinpepimut-S and GFH009. Furthermore, external factors such as geographical risks and fluctuating market conditions, including weaker metals prices, may complicate capital raising efforts and inhibit potential acquisition opportunities.

SLS has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of SELLAS Life Sciences Group and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About SELLAS Life Sciences Group (SLS) Forecast

Analysts have given SLS a Strong Buy based on their latest research and market trends.

According to 5 analysts, SLS has a Strong Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

SELLAS Life Sciences Group (SLS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.